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     A B S T R A C T : Background: We describe a 4-generation
       Dutch pedigree with a unique dominantly inherited clini-
       cal phenotype of a combined progressive chorea and
      cervical dystonia carrying a novel heterozygous dopa-
    mine D2 receptor ( ) variant.DRD2
        Objectives: The objective of this study was to identify
         the genetic cause of the disease and to further investi-
       gate the functional consequences of the genetic variant.
      Methods: After detailed clinical and neurological exami-
    nation, whole-exome sequencing was performed.
          Because a novel variant in the gene was found asDRD2
        the likely causative gene defect in our pedigree, we
         sequenced the gene in a cohort of 121 Hunting-DRD2
      ton-like cases with unknown genetic cause (Germany).
      Moreover, functional characterization of the variantDRD2
       included arrestin recruitment, G protein activation, and G
    protein-mediated inhibition of adenylyl cyclase
       determined in a cell model, and G protein-regulated
     inward-rectifying potassium channels measured in mid-
   brain slices of mice.
       Result: We identied a novel heterozygous variant c.634A
         > T, p.Ile212Phe in exon 5 of that cosegregatedDRD2
       with the clinical phenotype. Screening of the German
      cohort did not reveal additional putative disease-causing
     variants. We demonstrated that the D2S/L-I
212  F receptor
      exhibited increased agonist potency and constitutive acti-
         vation of G proteins in human embryonic kidney 239 cells
       as well as signicantly reduced arrestin3 recruitment. We
    furt her s howed t hat t he D 2S -I
212    F receptor exhibited aber-
      rant receptor function in mouse midbrain slices.
      Conclusions: Our results support an association between
 the novel p.Ile212Phe variant in DRD2, its modied D2
      receptor activity, and the hyperkinetic movement disorder
        reported in the 4-generation pedigree. © 2020 T he Authors .
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     Dopamine (DA) regulates diverse physiological func-
     tions, including movement, motivation, reward, and
learning. 1        DA acts on its G prote in-coupled DA recep-
      tors, D1, D2, D3, D4, and D5, 2,3   to modulate G
    protein-dependent and G protein-independent signaling
       cascades. Activation of the former results in dissocia-
          tion of the G protein heterotrimer into andαβγ α βγ
       subunits, each of which regulates other signaling pro-
     teins. The D2 receptor activates Gα i/o  subunits that
      inhibit adenylyl cyclase thereby decreasing cyclic adeno-
       sine monophosphate (cAMP) levels, a key regulator of
     many intracellular signaling pathways including ion
   channels and transcription factors. 2,3   The subunitsβγ
       bind directly to many proteins involved in intrace llular
     signaling, including G prot ein-coupled inwardly rectify-
      ing potas sium channels (GIRKs), which mediate D2
     autoreceptor inhibition of DA neuron ring. 4 One
     mechanism of G protein-independent signaling is
       recruitment of arrestin, which is implicated in both
      receptor desensitization and activation of G protein-
  independent signaling pathways. 5,6
     Dysfunction within dopaminergic pathways is linked
     to movement disorders including Parkinson s disease’
      and, to a certain extent, H untington s disease.’ 7-9 These
       diseases, and the dopaminergic pathway itself, are also
       associated with a wide range of psychiatric com-
     orbidities, including depression, anxiety, and hallucina-
tions. 10       Studies examining the genetic dep letion of DA
      receptors using transgenic mouse models have shown
         that a loss of D2 receptors results in impaired locomo-
        tion that is comparable to the clinical phe notype of
 Parkinson s disease,’ 11-13     while upregulation of the D2
       receptor in medium spiny projection neurons of the
      nucleus accumbens in mice results in enhanced
locomotion. 14
         H e r e , w e s t u d i e d a l a r g e D u t c h f a m i l y w i t h a d o m i -
    n a n t l y i n h e r i t e d h y p e r k i n e t i c m o v e m e n t d i s o r d e r ,
      i d e n t ie d a n o v e l D R D 2 v a r i a n t t h a t c o s e g r e g a t e d
       w i t h t h e m o v e m e n t d i s o r d e r , a n d e x c l u d e d t h e p o t e n -
         t i a l e x i s t e n c e o f a s i m i l a r g e n e t i c d e f e c t i n a G e r  m a n
      c o h o r t w i t h H u n t i n g t o n - l i k e c a s e s w i t h o u t a k n o w n
       g e n e t i c c a u s e . T h e n o v e l D 2 r e c e p t o r v a r i a n t a c t i v a t e s
    G p r o t e i n s m o r e e fc i e n t l y a n d r e c r u i t s a r r e s t i n 3 l e s s
       e f f e c t i v e l y t h a n t h e r e f e r e n c e r  e c e p t o r i n a c e l l u l a r
        m o d e l a n d a l s o e x h i b i t s a b e r r a n t f u n c t i o n i n D A n e u -
         r o n s i n m o u s e m i d b r a i n s l i c e s . T o t h e b e s t o f o u r
       k n o w l e d g e , t h i s i s t h e r s  t D R D 2 v a r i a n t w i t h
        i n v i t r o a n d e x v i v o d e m o n s t r a t e d d y s f u n c t i o n t o s e g -
      r e g a t e w i t h a m o v e m e n t d i s o r d e r d e s c r i b e d i n
h u m a n s  .
  Materials and Methods
       A full version of the Mate rials and Methods
       section can be found in the Supportin g Information.
 Patient Demographics
        A total of 8 family members from this 4-generation
      pedigree underwent clinical anam nesis and a standard-
      ized neurological examination by 2 neurologists (C.C.S.
        and M.A.J.) who were blinded to patient and relation-
       ship status. Their basic characteristics are describ ed in
       Table 1. In addition, cognitive function was tested
      using the Mini-Mental State Examination (MMSE) and
      Frontal Assessment Battery (FAB). All methods were
      performed in accordance with the relevant guidelines
       and regulations. All patients gave written informed con -
       sent. In addition, a cohort with Huntington -like pheno-
       types was collected from the Institute of Medical
       Genetics and Applied Genomics of the Universit y of
     Tuebingen in Germany. This Huntington s disease like’ –
       cohort was composed of sporadic and familia l cases
        with chorea of unknown genetic origin. Chorea was the
         only symptom in 48 patients, 13 patients also had dys-
      tonia, 23 patients had accompanying memory prob-
      lems, 13 patien ts also had psychiatric problems,13
        patients had ataxia as well, 8 patients had accompany-
      ing orofacial dyskinesia, and 3 had accompanying
       tremor. The study was performed in accordance with
        the Declaration of Helsinki and approved by the Medi-
       cal Ethical Committee s of the University Medical Cen-
      ter Groningen and the University of Tuebingen.
 Genetic Studies
         The proband of the f amily was tested for an in-house
       dystonia gene panel (T a ble S1) and repeat expansi o ns
      (CAG, CAA, CT G) in HTT; Hunti ngton’s disease-like
      (HDL) genes including PRNP (HDL-1), JP H3 (HD L-2),
       and TBP (HDL-4/ Spinocerebellar ataxia (SCA) type 17);
   and benign hereditary chorea (NKX 2-1) (Table S2). When
      these tests came back negative, whole-exome sequencing
      (WES) was performed using Macrogen (Macrogen Inc.).
       Data derived from WES were analyzed using Cartagenia
     software (Agilent T echno logies). The p.Ile212Phe variant
      was conrmed using Sanger sequencing w ith forw ard
5’GGACATGAATGGGCTCTTGT30   and reverse 50TCC
TGGGAATT C CTTTAGCC30    primers. In the German
        cohort, s e quencing of t he DRD2 codi n g region was per-
      formed using Sanger sequencing ( for pr imer sequences,
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       see Table S3). Mutation analysis w as perfor m ed usi ng
     Mutation Surveyor version 5.1.2 (Softgenetics LLC).
    Positron Emission Tomography Scan Imaging
      In vivo D2 receptor positron emissi on tomography
     (PET) imaging was performed using [ 11  C]raclopride, a
 selective DRD2/3     antagonist, on individuals III:8, IV:4,
        and IV:5. Subjects were asked to refrain from smoking
         for 12 hours and from drinking alcohol for 24 hours
           and to not eat 4 hours prior to the PET scan. Striatal
 DA D 2/3      receptor availab ility was measured following a
     60-minute dynamic acquisition protocol after a
       1-minute bolus injection of 200 (204 220) MBq of–
[ 11       C]raclopride on a Siemens Biograph mCT system
       (Siemens Medical Solutions USA, Inc). All images were
     spatially normalized using PMO D (PMOD Technolo-
        gies Ltd). Brain regions were de ned using the Ham-
       mers Atlas. Bindi ng potential s (BPs) were calculated for
       each patient using a simpli ed reference tissue model,
        using the cerebellum as the reference region, and com-
      pared with BPs of healthy subjects (health y,
   nonsmoking, nonmedicated subjects). Age-dependent
        decline of BP values was taken into account as
    described in Nakajima and colleagues. 15
  Recombinant cDNA Constructs
         Descriptions of the plasmids used in this study can be
    found in the Supporting Information.
   Bioluminescence Resonance Energy Transfer
Assays
       After 48 hours of transfection, human embryonic kid-
       ney 239 (HEK293) cells were harve sted, washed, and
    resuspended in phosphate-buffered saline containing
  0.1 mM CaCl2    and 0.5 mM MgCl2   and plated at
     100,000 cells /well in 96-well OptiPlates (PerkinElmer
        Life Sciences). Emission of the donor (460 m) and
       acceptor (535 m) was measu red at several timepoints
       after adding quinpirole followed by the luciferase sub-
       strate coelenterazine at room temperat ure, and biolu-h
     minescence resonance energy transfer (BRET) ratios
    were calculated as previously described. 16,17
 Data Analysis
    Concentration-response curves and radioligand satu-
       ration binding curves were analyzed by nonlinear regres-
        sion using Prism 7 or 8 (GraphPad Software Inc.).
      Statistical signi cance between 2 groups was determined
       using the Student s -test. For comparisons with more’ t
                   FIG. 1. AFour-generation pedigree and am ino acid sequence homology. ( ) Four-generation pedigree carrying the missense variant c.634A > T, p.
                      Ile212Phe in . Genetic analysis was performed in the individuals indicated by DNA. Proband is indicat ed by an arrow. Individuals ma rked by anDRD2 “ ”
                     asterisk underwent whole-exome sequencing. The variant (c.634A > T) was identi ed in 5 affected subjects and was abse nt in 3 unaffected subjects.
                     Male = square, female = circle, sex unknown = hexagon. Filled symbo ls = affected. Open symbols = unaffected. Sequence alignments showing the
                       amino acid sequence identity of the affected am ino acids in ( ) multipl e species orthologs of DRD2 and ( ) among the human dopamine receptor fam-B C
                         ily. The mutated amino acid isoleucine at position 212 is indicated by the vertical box. The region of ar restin-binding (IYIV) in is indicated by theDRD2
        horizontal box. [Color gure can be viewed at wileyonlinelibrary.com ]
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         than 2 groups, we used analysis of variance followed by
      the Tukey s multiple comparisons test. For [’ 3H]spi-
       perone binding, the geometric mean (mean of logKd)
      was calculated and used for statistical comparison.
Results
     Identi cation of a Family with Unique
  Hyperkinetic Movement Disorder
       Patient demographics are presented in Table 1. The
        proband (III:8; Fig. 1A) visited our outpatient clinic at
       age 60 years. Her history revealed dance-like irregular
       movements and abnormal posturing of the head that
         started at age 20 years, progressed over time, and extended
        to orofacial involvement (Video S1). In addition, the subject
       reported that, with increasing age, she developed memory
       problems and generalized anxiety with panic attacks. Gen-
        eralized anxiety was treated with sertraline, which gave no
      perceptible relief of the irregular movements. Neurological
      examination showed choreatic movements of the orofacial
        region an d all ex tremities, dystonic posturing of the head,
      and eye movement apraxia. Cognitive function (MMSE
        and FAB) was normal. The proband’s older si ster by
          2 years (III:6; Fig. 1A) was noted to have abnormal postur-
          ing of the head an d wringing movements of the hands in
       early childhood. Her symptoms progressed over time, and
      during stressful situations she developed involuntary move-
         ments of the eyebrows and upper lip. Starting at age
        30, she suffered from agoraphobia, which w as treated with
         paroxetine but did not lead to reported improvement of the
      irregular movements. At age 62, neurolo gical examination
      revealed a phenotype closely resemb ling the proband’s
        (III:8), wi th choreatic movements of the t runk, head, and
        orofacial region and dystonic posturing of the head. Her
    MMSE and FAB were normal.
      The eldest affected sister (III:4) developed progressive
       irregular movements of the head, trunk, arms, and
       hands starting in early childhood, f ollowed by dystonic
         posturing of the neck and dyskinesia of the mouth. At
        age 64 years, she exh ibited orofacial, head, truncal, and
      limb choreatic movements. She also developed dystonic
        posturing of the right arm, right shoulder, and ngers.
     Her MMSE and FAB were normal.
       Affected male IV:4 (Fig. 1A, Table 1) started
      exhibiting irregular choreatic movements of the head,
         trunk, and upper extrem ities at age 14 years. He later
       developed abnormal posturing of the neck and upper
        extremities. Upon examinati on at age 30 years, he had
       choreatic movements of the head, trunk, and upper
      extremities and eye movement apraxia. Dystonic pos-
         turing of the head, left shoulder, and both arms was
         also present. His younger sister (IV:5; Fig. 1A, Table 1)
        developed similar symptoms at age 18 years and also
       followed a similar course. At examination at age
        29 years, she showed mild choreatic movements of the
        head, trunk, and all extremities together with mild dys-
         tonia of the neck and right shoulder. No cognitive or
       psychiatric symptoms were detected in IV:4 and IV:5.
    Putative Pathogenic Novel VariantDRD2
     Segregates with the Clinical Phenotype within
 the Family
       To identify the genetic cause underlying the progressive
       chorea and dystonia phenotype within this family, and
       because proband III:8 tested negative for mutations in
        known genes present in an in-house gene panel (design
         2017, Table S1) and was negative for repeat expansions in
     the HTT, H DL gen es JPH3 (HDL-2) and TBP [HDL-4/
     spinocerebellar ataxia (SCA17)], and benign hereditary
       chorea (NKX2-1) (Table S2), WES was performed in
       affected individuals III:8 and IV:5 and unaffected family
         member III:14. We then generate d an overview of all het-
       erozygous variants that were shared between the affected
        cases but not present in the unaffected family member.
         After removing all variants annotated as benign in our in-
        house genetic pipeline and all variants present in the
      GnomAD browser (assessed December 2018), we identi-
         ed 4 missense variants. Two had a relatively high minor
       allele frequency and were therefore excluded as potential
          candidates, and 1 variant turned out to be a false positive
        and was therefore excluded (Table S4). The fourth variant
         was a novel heterozygous variant in exon 5 of DRD2
       [126450]: c .634A > T, p.Ile212Phe. Segregation of this
        variant with the clinical phenotype was conrmed in a
         total of 5 clinically affected and 3 clinical ly unaffected fam-
        ily members (Fig. 1A). The pathogenicity of this variant
        was assessed by the in silico prediction programs Sorting
     Intolerant From Tolerant (SIFT), Polyphen2, and
     MutationTaster and the tool Combined Annotation
      Dependant Depletion (CADD) (Table S5), which all
        predicted the variant to be damaging. The putative patho-
        genicity of the novel DRD2 variant is further substantiated
          by the fact that the exchange of amino acids in the
        211–213 region seems quite intolerant, as no missense var-
        iants are reported at these positions in GnomAD (assessed
        January 2020). Moreover, the isoleucine at this position is
       highly conserved among orthologous genes of the D2
        receptor (Fig. 1B) and among human DA r eceptor sub-
          types (Fig. 1C), with the exception of the D4 receptor. The
        variant results i n a change of the strongly hydrophobic
        amino acid isoleucine at position 212 into a hydrophobic
       and aromatic phenylalanine that is predicted to mildly
       alter the secondary structure of this intracellular extension
      of the fth transmembrane domain ( TM5) (Grantham
 score 21).
      Variants in May Only Rarely AssociateDRD2
  with Huntington-Like Phenotypes
        To assess whether this variant was present in other
    populations with Huntington-like phenotypes, we
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         screened a cohort of 121 DNA samples collected by the
       Institute of Medical Genetics and Applied Genomics of
       the University of Tuebingen, G ermany, for rare varian ts
       throughout the coding region of (see MaterialsDR D2
      and Methods). We identi ed several relatively common
       variants in multiple cases and 1 rare variant,
         c.62517C > T, p.Pro347Ser in exon 7 of , thatDRD2
        was predicted in silico to be benign (Ta ble S6).
       Cerebral D2 Receptor Levels Are Not Altered in
Patients
         To assess the impact of variant c.634A > T, p.Ile212Phe
       on cerebral DRD2 expression levels, we performed D2
    receptor PET imaging using [ 11   C]raclopride, a selective
DRD2/3       antagonist, on individuals III:8, IV:4, and IV:5.
        When an age-dependent decline was taken into account as
    described in Nakajima and colleagues, 15    the BPs of the
       caudate nucleus of patients were within normal range
        (Table S7). When age-dependent declines in BPs of the
        putamen were considered, patient values were close to the
          lower limit of the normal range but were still within nor-
 mal range.
     The p.Ile212Phe Variant Impairs D2 Receptor
  Recruitment of Arrestin3
        To investigate the effect of the sequence polymorphism on
        D2 receptor function, we investigated the ability of the
       mutant D2 receptor to recruit arrestin3. We hypothesized
         that the arrestin3 recruitment may be affected, as the p.
         Ile212Phe variant is located in a 4 amino acid motif
       (212–215), which was previously linked to arrestin3 recruit-
    ment to the D2 receptor. 17,18   Arrestin3 recruitment is
      required for terminating G protein-coupled receptor signal-
      ing, facilitating receptor internalization, and engaging non-
    canonical, G protein-independent signaling path ways.19
        Because the D2 receptor has alternatively spliced long and
        short isoforms t hat differ in the third cytoplasmic loop,
         which is involved in binding arrestin and G proteins, we
        tested the consequence of the p.Ile212Phe variant in both.
      The D2 receptor agonist quinpirole produced a
    concentration-dependent increase in arrestin3 recruitment
      for both wild t ype ( WT) and I 212     F D2 receptors, b ut maxi-
     mal recruitment of arrestin3 by D2 S -I
212F and D2 L-I
212F
           was 68% ± 1% and 48% ± 2%, respectively, of the maxi-
   mal recruitment by D2S/L      -WT (Fig. 2A,B; Table S8). There
        was also a s ignicant interaction between genotype and the
        time course of maximal arrestin3 recruitment (Fig. 2 legend),
        with the BRET signal decreasing more rapidly for D2S/L-
I 212F than for D2S/L      -WT (Fig. 2 C,D). In addition, the
      potency of quinpirole was modestly but signicantly
  enhanced for D2S/L-I
212F compared with D2S/L -WT
      (Table S8). The membrane expression of D2S-I
212 F and
D2 L-I
212        F receptors was 50% and 38% of D2S/L -WT
        expression, respectively (Table S9), b ut did not explain the
      lowered ability to recruit arrestin3 by D2-I 212    F, as a similar
       impairment of arrestin3 recruitment was observed in an
       independent experiment where a doubled amount of D2L-
I212        F DNA was transfected (data not shown). Coexpression
   of D2-WT and D2-I212F (D2S-WT/I
212 F and D2L-WT/I
212 F)
         in cells resulted in arrestin3 recruitment that was more simi-
     lar to D 2-WT than to D2-I212     F (Fig. 2A-D; Table S8).
D2-I
212
     F Receptors Exhibit Increased Basal G
    Protein Activation and Enhanced Agonist
Potency
       To investigate how the p.Ile212Phe variant in DRD2
   could affect the Gα i/o   protein mediated signaling path-–
      way, we measured the ability of D2-I212   F to activate
Gαi1      protein and to inhibit forskolin-stimulated activa-
        tion of adenylyl cyclase. The potency of quinpirole for
  activation of Gαi1    was signi cantly increased for
D2-I212   F (both D2 S  and D2L    ) relative to D2-WT,
        re ected in the leftward shift in the dose-response curve
          (Fig. 3A,B; Table S8). The shift in potency was also seen
   in cells coexpressing D2S-WT/I
212   F and D2 L-WT/
I212    F. Cells expressing D2-I 212    F also exhibited increased
        basal G protein activation (Fig. 3A,B; mean ± SEM:
       −0.01% ± 0.01% of maximal stimulation for D2 S-WT
     vs. 35% ± 6% for D2 S-I
212        F, < 0.001, n = 4, andP
    0.01% ± 0.02% for D2L       -WT vs. 26 ± 10% for D2L -
I212          F, < 0.05, n = 4). G protein-coupled receptorsP
       exhibit differing degrees of constitutive activity (ie, sig-
        naling in the absence of agonist), and many mutations
  increase constitutive activity. 20    Upon correction for base-
     line activity, maximal activation of Gαi1   did not differ
      signi cantly among the different genotypes (Table S8).
      The increased agonist potency and constitutive activity
     occurred despite signi cantly lower membrane expres-
  sion of D2-I212      F compared with D2-WT (Table S9).
      We then investigated cAMP accumulation in cells
 expressing D2S/L  -WT, D2 S/L -I
212F or D2 S/L-WT/I
212F and
     cAMP sensor using YFP-Epac-Rluc (CAMYEL), a
  BRET-based cAMP sensor.17 D2S/L-I
212  F showed
     increased quinpirole potency for inhibiting forskolin-
    induced cAMP compared with D2 S/L   -WT, reecte d by
    left-shifted concentration-response curves (Fig. 3C,D;
       Table S8). No signicant difference was observed between
  D2-WT and D2-I212      F in maximal inhibition of cAMP
      accumulation (Table S8). In these experiments, D2S/L-
I212         F was again expressed less abundantly at the plasma
   membrane compared wi th D2S/L    -WT ( Table S9). D2S/L-
WT/I212      F signicantly differed in quinpirole potency com-
   pared with both D2S/L   -WT and D2 S/L-I
212   F (Table S8).
 Altered D2-I212    F Receptor-GIRK Currents and
    Inhibitory Postsynaptic Currents in Mouse
 Midbrain Slices
       D2 autoreceptors on DA neurons in the midbrain
      produce G protein-mediated activation of GIRK cur-
       rents that hyperpolarize the neurons and thus decrease
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    cell ring and DA release. 4,21    To investigate the effect
         of the p.Ile212Phe variant on D2 receptor activity in a
      more physiological environment, we assessed D2 recep-
     tor regulation of GIRKs in neurons.22   We used an
      adeno-associated virus (AAV) vector to express D2 S -
  WT or D2S -I
212       F in DA neurons present in midbrain
          slices of mice in which the D2 receptor has been geneti-
     cally deleted (Supporting Information Materials and
    Methods). Whole-cell voltage-clamp recordings were
    performed in green uorescent protein(GFP)-marked
   neurons expr essing either D2 S   -WT or D2S -I
212  F. D2
      receptor-GIRK currents in response to bath-applied DA
       or quinpirole were signi cantly smaller in D A neurons
 expressing D2 S-I
212     F compared with those expressing
D2 S       -WT (Fig. S1B,E). During continued agonist applica-
       tion, the D2-GIRK currents declined equally in ampli-
  tude for D2S   -WT and D2S -I
212     F (Fig. S1C). We then
       electrically stimulated the slice to produce D2 receptor-
     GIRK inhibitory postsynaptic currents (IPSCs) in
      response to somatodendritic DA release. In neurons
 expr essing D2 S-I
212       F, the IPSCs peaked later (for both
           1 and 5 pulses at 40 Hz; Fig. 4C,F) and had signi cantly
      longer half-widths (Fig. 4D,G) compared with D2 S -WT.
       In addition, 5-pulse IPSCs were signi cantly larger for
D2 S    -WT compared with D2S -I
212    F (Fig. 4B), al though
         not for 1 pulse IPSCs (Fig. 4E). While recording, sponta-
   neous D2 receptor-GIRK IPSCs23    were detected in DA
   neurons expressing either D2 S   -WT or D2S-I
212F
        (Fig. 4H). The amplitudes of the spontaneous IPSCs did
      not differ betwee n DA neurons expressing D2S  -WT or
D2S-I
212        F (Fig. 4I), but their width was signi cantly
    greater in neurons expressing D2 S-I
212   F (Fig. 4J).
Discussion
       We here report the identi cation of a gain-of-function
        variant in that cosegregates with a mixed phe-DRD2
         notype of chorea and dystonia in a large Dutch family.
         The putative pathogenic effect of the novel c.634A > T,
        p.Ile212Phe variant in was supported by in sil-DRD2
        ico prediction models. Screening of a German cohort of
      Huntington-like cases for variants suggests thatDRD2
       variants in may only rarely associate withDRD2
     Huntington-like phenotypes. We further provide sub-
        stantial functional evidence using in vitro and ex vivo
         models that the clinical phenotype may be the result of
       a constitutively active D2 receptor leading to over-
     stimulation of G protein-dependent signaling derived
       from a combination of increased signaling ef ciency of
                 FIG. 2. A,BArrestin recruitment in response to quinpirole. ( ) Dose-response curves for arrestin recruitment mediated by D2-WT, D2-I 212   F, and D2-WT/
I212                      F in response to a 20-minute stimulation with quinpirole. Results are expressed as a percentage of maximum arrestin recruitment by D2-WT. ( )A
  Data for D2 S    . (B) Data for D2 L                  . (C,D) Time course of maximal recruitment of arrestin for each condition. Basal response was subtracted from the ma xi-
                   mal quinpirole stimulation response for each indicated time. Maximal recruitment was normalized to its initial response (1-minute response). There was
              a signi cant interaction between genotype and time for maximal recruitment (2-way analysis of variance: F 12,63       = 3.628, = 0.0004 for D2P S  , and
F 12,42       = 4.304, = 0.0002 for D2P L                  ). Values plotted are mean ± SD of 4 ( ) and 3 ( ) independent experiments performed in quadruplicate.A,C B,D
                          * < 0.05, ** < 0.01, and *** < 0.001 compared to D2-WT and < 0.05, < 0.01, and < 0.001 compared to D2-WT/IP P P †P ††P †††P 212   F, Tukey s multiple’
              comparisons test. Emax, maximum response; WT, wild type. [Color gure can be viewed at wileyonlinelibrary.com ]
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      the G protein-dependent signaling itself and reduced
  activation of arrestin.
       The importance of amino acid isoleucine at position
       212 for D2 receptor functioning is substantiated by
       prior work reporting that changing the amino acids
        212 215 into alanines results in a D2 receptor that–
     lacks arrestin3 recruitm ent upon agonist stimulation,
       whereas mutating the amino acids 213 215 (D2-A3) or–
      214 215 (D2-A2) into alanines only partially decreases–
  agonist-induced arrestin3 recruitment.17,18  The reason
 that D2-I212        F is less expressed at the plasma membrane
          is not yet known, however this w as not a direct cause
      for the reduced arrestin3 recruitment, as experiments
     with double the amount of D 2 L -I
212    F DNA showed a
      similar impairment of arrestin3 recruitment upon ago-
       nist stimulation. Our results indicate that isoleucine at
      position 212 is key in agonist-dependent arrestin3
        recruitment and binding by the D2 receptor, and when
       changed into a phenylalan ine would lead to aberrant
 receptor functioning.
        The role of arrestin3 in movement regulation is further
     substantiated in animal models of Par k inson’s disease
     where ar restin3 knockout reduces the benecial
      locomotor effect of levodopa and enhances dys kinesias,
      including tongue pr otrusion s and continuous r apid limb
     movements, whereas overexpressi o n of arrestin3 reduces
     dyskinesias while maintaining benecial locomot o r effects
 of levodopa. 24      These dyskinesias are equivalent to abnor-
        mal orolingual and l imb movements in humans and simi-
          lar to the phenotype seen in the family we ar e reporting.
        In addit ion , expression of a mutant D2 receptor that
         recruits arrestin3, but has little ability t o act ivate G pr o -
    teins (D2R-arrestin-biased mutant, D2R-ARB), reverses
       the reduced locomotion phenot ype in D2 receptor knock-
      out mice, and overexpression of D2R-ARB signicantly
     enhances locomotion compared with control mice.25
         In our report, 2 of 5 affected family members were
         diagnosed with an anxiety disorder at a later age. This
         was not present in the unaffected family members of sim-
        ilar age. DRD2 has been linked to psychiatric problems
  in myoclonus dystonia.26,27   However, the underlying
      mechanism is unknown. Within our family constitutive
       activation of the G protein-dependent pathway may give
       a potential explanation for the psychiatric symptoms of
        generalized anxiety and panic attacks as the current main
      treatment for psychiatric diseases are DRD2 antagonists.
            FIG. 3. A,BProtein activation in response to quinpirole. ( ) Dose-response curves for Gα i1      protein activation mediated by D2-WT, D2-I
212
  F, and D2-WT/
I
212
                   F in response to a 10-minute stimulation with quinpirole. Results are expressed as a percentage of maximum G protein activation by–
                   D2-WT. Values plotted represent mean ± SD of 4 independent experiments performed in quadruplicate. ( ) Dose-response curves for the inhibitionC,D
       of forskolin-st imulated cAMP accumulation mediated by D2-WT, D2-I
212
  F, and D2-WT/I
212
          F in response to incubation with quinpirole for 10 minutes in
                      the presence of 10 M forskolin. Results are expressed as a percentage of maximum cAMP accu mulation for each condition. Values plotted are mean
                ± SD of 4 ( C D) and 6 ( ) independent experiments performed in triplicate. Left and right panels depict data for D2S  and D2 L    , respectively . cAMP, cyclic
                adenosine monophosp hate; Emax, maximum response; FSK, forskolin; WT, wild type. [Color gure can be viewed at wileyonlinelibrary.com]
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  FIG. 4. D2 S                receptor-GIRK IPSCs in dopamine neurons. ( ) Example recordings of electrically stimulat ed IPSCs from neurons expressing D2A S -WT
           (5 stimuli at 40 Hz [black] and 1 stimulus [gray]) and D2S -I
212
                  F (5 stimuli at 40 Hz [black] and 1 stimulus [gray]). When 5 stimuli were used to elicit IPSCs,
  neurons expressing D2S                      -WT had ( ) larger amplitude IPSCs (Student s -test; = 2.2141, = 0.043), ( ) faster time to peak (Student s test; 5 stimula-B ’ t t P C ’ t-
                 tions, = 5.1519, < 0.001), and ( ) shorter half-width compared to IPSCs in neuro ns expressing D2t P D S-I
212
         F (N = 7 cells from 3 animals for D2 S -WT,
        N = 10 cells from 3 animals for D2 S-I
212
                     F; Student s t-test; for 5 stimulations, = 5.3117, < 0.001). When 1 stimulus was used to elicit IPSCs, ( ) neu-’ t P E
  rons expressing D2 S   -WT and D2S -I
212
                     F had IPSCs that did not differ signi cantly in amplitude (Student s test; = 1.88 38, = 0.086), but ( ) the IPSC ’ t- t P F
                      time to peak (Student s -test; 1 stimulation, = 4.5137, < 0.001) and ( ) half-widths were signi cantly shorter in neurons expressing D2’ t t P G  S  -WT com-
  pared with D2 S-I
212
         F (N = 5 cells from 2 animals for D2 S          -WT, N = 8 cells from 3 animals for D2S-I
212
        F; Student s -test; for 1 stimulation, = 6.6569,’ t t
                 P < 0.001). ( ) Averages of spontaneous D2 receptor IPSCs from DA neurons expressing D2-WT (black) or D2-IH
212
     F (gray). ( ) The average spontaneousI
        IPSC amplitudes did not differ between neurons expressing D2 S   -WT and D2S -I
212
         F (N = 61 events from 3 animals for D2S       -WT, N = 50 events from 5
  animals for D2S-I
212
                      F; Student s -test; = 0.72164, = 0.4721). (J) The average spontaneous IPSC width at 20% of peak was signi cantly longer in’ t t P 
   DA neurons expressing D2S -I
212
     F compared with those expressing D2 S          -WT (N = 61 events from 3 animals for D2S        -WT, N = 50 events from 5 animals
 for D2S -I
212
                        F; Student s test; = 14.34 1, < 0.0001). * < 0.05; ** < 0.01; *** < 0.001 compared with D2-WT. IPSCs, inhibitor y postsynaptic cur-’ t- t P P P P
        rents; n.s., not signi cant; stims, stimulations ; WT, wild type.
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      Moreover, mice treated with D2 receptor antagonists
       show reduced anxiety measured by elevated plus maze
 test scores.28,29       This effect was also observed in patients
      with psychotic disorders, where DA antagonists reduce
 social anxiety.30      Together, these lines of evidence suggest
     that arrestin3-mediated D2 receptor signaling regulates
       locomotion, while dyskinesia is a consequence of G
protein-activation.
       Our current results of G protein activation support
      the literature ndings. Together, the G protein-
      activation and cAMP data strongly suggest enhanced
    ef ciency of coupling of D2 S/L-I
212     F to G proteins com-
  pared with D2 S/L    -WT. Thus, the D2-I
212   F receptor may
       be biased towards G protein-mediated signaling, in part
     re ecting increased D2 receptor constitu tive activity.
      To furthe r evaluate D 2 receptor activation , we
        assessed D2 receptor regulation of GIRKs in DA neu-
         rons. The data derived from the midbrain slices of mice
   expressing D2-WT or D2-I 212     F support the notion of
     aberrant G protein-mediated signaling by D2S -
I 212        F. We hypothesize that the reduced peak current
      amplitude under some conditions in DA neurons
 expressing D2-I 212      F may re ect low receptor expr ession
          as seen in HEK293 cells. The time to peak and IPSC
      half-width were consistent betwee n 1-pulse or 5-puls e
  stimulations for D2S -I
212     F, indicating that the pro-
    longed IPSC mediated by D2S -I
212   F reects a change
      intrinsic to the receptor-GIR K interaction rather than
        altered DA release or uptake. The increased peak width
     seen in IPSCs mediated by D2-I212    F is consistent with
      enhanced activation of G proteins by D2-I212  F. The
        slow onset and decay of the response to D2-I 212  F may
       indicate that recruitment of arrestin is respo nsible for
         the rapid on and off rates of response to D2-WT.
    Unfortunately, no additional Huntington s disease’ –
       like cohorts were available for screen ing besides the
       cohort from Germany. Future studies are needed to
        con rm whether mutatio ns in are a more com- DRD2
         mon cause of chorea. When a patient with an early
    onset autosomal dominant chorea-dystonia phenotype
        presents at any outpatient clinic, we may recommend to
       test rst for repeat expansions in early-onset chorea
       genes, including , HDL genes, and benign heredi -HTT
       tary chorea genes, followed by an up-to-date dystonia
      gene panel and subsequently Human Phenotype Ontol-
     ogy (HPO)-labelled dystonia and chorea genes .
         In short, the D2 receptor is well established in regula-
       tion of movement, and overstimulation of G protein-
       dependent signaling by the mutant D2 receptor together
       with reduced arrestin recruitment and activation may be
      the cause of the hyperkinetic movement disorder
        described in this study. Our ndings may have important
      therapeutic implications because a biased D2 receptor
      ligand that decreases G protein-mediated signaling, while
      sparing arrestin-mediated signaling, might be an effective
    treatment in hyperkinetic movement disorders.
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